GLP-1 Drugs and Sleep Apnea: Can Ozempic Reverse OSA?
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-06-03 · 8 min read
SURMOUNT-OSA showed tirzepatide cut sleep apnea severity 63%. Here is who can come off CPAP — and who absolutely should not.
The First Drug to Reduce OSA Severity
SURMOUNT-OSA (NEJM 2024, 1-year extension 2026) tested tirzepatide in 469 adults with moderate-severe OSA:
- AHI reduction: 30 events/hr → 11 events/hr (mean −63%)
- 43% of participants reached complete OSA remission criteria
- BP, hsCRP, and metabolic markers all improved
Medicare Coverage (2026)
CMS approved tirzepatide (Zepbound) for OSA in adults with BMI ≥ 30 starting March 2026. This is the first GLP-1 with an OSA-specific indication.
Should You Stop CPAP?
Not yet. Wait until:
- Repeat sleep study confirms AHI < 5
- Daytime sleepiness (Epworth) is normal
- Your sleep doctor signs off
Until then, keep using your CPAP. Need a new mask? See our CPAP masks selection.
Risks of Premature CPAP Discontinuation
- AFib triggered by nocturnal hypoxia
- Daytime sleepiness causing MVA risk
- Loss of cardiac benefit on tirzepatide alone